10.07.25 -- STREAM Edition: Inside Sanofi's Genomic Medicine Vision With Mike Quigley, Ph.D.

AI is transforming cell therapy manufacturing and enabling more personalized treatments. Explore how to navigate innovation in a fast-moving therapeutic landscape with actionable insights.

In this Cell & Gene Live segment, experts discuss validating impurity removal in allogeneic cell therapies involves collecting data from early research through GMP manufacturing to support regulatory submissions.

Learn how leveraging the expertise and capabilities of an experienced partner is a key factor in optimizing AAV processes using Design of Experiment (DoE), thereby reducing variability and risk.

Uncover the secrets behind successes in commercializing and producing commercial cell and gene therapies, including establishing standards of every day, manufacturing operational excellence.

Whether you are a researcher, scientist, or industry professional, this video will provide valuable insights into our large volume liquids manufacturing capabilities.

Join us in this video as we delve into invaluable tips, cutting-edge tools, and unwavering support that Cytiva offers to facilitate your documentation progress.

On episode 112 of Cell & Gene: The Podcast, Michael Quigley, Ph.D., Chief Scientific Officer and Global Head of Research at Sanofi talks about the establishment of Sanofi’s dedicated Genomic Medicine Unit (GMU). Dr. Quigley emphasizes in vivo delivery and process optimization to improve patient experience, scalability, and global access.